WHAT IS THE FUTURE OF VALUE-BASED CARE?

Commercial risk will be a critical catalyst of progress – it’s complicated, but is it possible? We think so.

X

Sponsored Content

How Carle Health advances early lung cancer detection through incidental findings

    Overview

    In 2017, Carle Health developed a lung nodule program that utilizes artificial intelligence (AI) solutions to aid in identifying incidental pulmonary nodules. Organizational alignment around this program has lead to earlier lung cancer detection and improved patient outcomes.

    Download the accompanying slides to learn the keys to their success.

    Sponsored by
    The Lung Ambition Alliance logo

    This report is sponsored by AstraZeneca, in partnership with The Lung Ambition Alliance. Advisory Board experts wrote the report, conducting the underlying research independently and objectively. AstraZeneca had the opportunity to review the report.

     

    About the sponsor

    The Lung Ambition Alliance, a global coalition with partners across disciplines in over 50 countries, was formed to combat lung cancer through accelerating innovation and driving forward meaningful improvements for people with lung cancer. We do this by advocating for improved approaches in three areas: screening and early diagnosis, accelerated delivery of innovative medicine, and improved quality care.

    Learn more about The Lung Ambition Alliance

    This report is sponsored by AstraZeneca, an Advisory Board member organization. Representatives of AstraZeneca helped select the topics and issues addressed. Advisory Board experts wrote the report, maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.

    To learn more, view our editorial guidelines.

    Have a Question?

    x

    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.